Eventide Asset Management BHVN Position
Exited6-Fund ConvergenceEventide Asset Management exited their position in Biohaven Pharmaceutical Holding (BHVN) in Q3 2025, after holding the stock for 8 quarters.
The position was first reported in Q4 2023 and has been tracked across 8 quarterly 13F filings.
BHVN is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 20.3% of float with 9.2 days to cover, indicating significant bearish positioning against the stock.
About Biohaven Pharmaceutical Holding
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Full company profile →Short Interest
20.3%
9.2 days to cover
Eventide Asset Management BHVN Position History
Frequently Asked Questions
Does Eventide Asset Management own BHVN?
No. Eventide Asset Management exited their position in Biohaven Pharmaceutical Holding (BHVN) in Q3 2025. They previously held the stock for 8 quarters.
How many hedge funds own BHVN?
6 specialist biotech hedge funds currently hold BHVN, including Perceptive Advisors, Redmile Group, Cormorant Asset Management and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy BHVN?
Eventide Asset Management's position in BHVN was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's BHVN position increasing or decreasing?
Eventide Asset Management completely exited their BHVN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BHVNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →